Efficacy and Safety of Deferasirox (Exjade®) in Patients with β-Thalassemia Major Treated for up to 5 Years

被引：0

作者：

Cappellini, M. Domenica ^{[1
]}

Perrotta, Silverio ^{[2
]}

Agaoglu, Leyla ^{[3
]}

Aydinok, Yesim ^{[4
]}

Capra, Marcello ^{[5
]}

Canatan, Duran ^{[6
]}

Drelichman, Guillermo ^{[7
]}

Kilinc, Yurdanur ^{[8
]}

Magnano, Carmelo ^{[9
]}

Porter, John B. ^{[10
]}

Piga, Antonio ^{[11
]}

Griffel, Louis ^{[12
]}

Lagrone, Darlene ^{[12
]}

Clark, Joan ^{[13
]}

Kattamis, Antonis ^{[14
]}

机构：

[1] Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Milan, Italy

[2] I Policlin II Univ Napoli, Naples, Italy

[3] Istanbul Univ, Istanbul Sch Med, Div Pediat Hematol Oncol, Istanbul, Turkey

[4] Ege Univ, Fac Med, Izmir, Turkey

[5] Osped Civ & Benefratelli G Di Cristina M Ascoli, Palermo, Italy

[6] Suleyman Demirel Univ, Fac Med, TR-32200 Isparta, Turkey

[7] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina

[8] Cukurova Univ, Fac Med, Dept Pediat Hem Onc, Adana, Turkey

[9] Az Osped Riliervo Nazl & Alta Spec Garibaldi, Catania, Italy

[10] UCL, London, England

[11] Univ Turin, Turin, Italy

[12] Novartis Pharmaceut, E Hanover, NJ USA

[13] Novartis Pharma AG, Basel, Switzerland

[14] Univ Athens, Dept Pediat 1, Athens, Greece

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1558 / 1559

页数：2

共 50 条

[1] Long-Term Safety and Efficacy of Deferasirox (Exjade®) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years
Vichinsky, Elliott
Bernaudin, Francoise
Forni, Gian Luca
Gardner, Renee
Hassell, Kathryn
Heeney, Matthew M.
Inusa, Baba
Kutlar, Abdullah
Lane, Peter A.
Mathias, Liesl
Porter, John B.
Tebbi, Cameron K.
Wilson, Felicia L.
Griffel, Louis
Deng, Wei
Giannone, Vanessa
Coates, Thomas D.
BLOOD, 2010, 116 (21) : 367 - 368
[2] Continued Improvement and Normalization of Myocardial T2*In Patients with β-thalassemia Major Treated With Deferasirox (Exjade®) for up to 3 Years
Pennell, Dudley
Porter, John B.
Cappellini, Maria Domenica
Chan, Lee Lee
El-Beshlawy, Amal
Aydinok, Yesim
Ibrahim, Hishamshah
Li, Chi-Kong
Viprakasit, Vip
Elalfy, Mohsen Saleh
Kattamis, Antonis
Smith, Gillian
Habr, Dany
Domokos, Gabor
Roubert, Bernard
Taher, Ali
BLOOD, 2010, 116 (21) : 1735 - 1736
[3] Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up
Cappellini, M. Domenica
Bejaoui, Mohamed
Agaoglu, Leyla
Canatan, Duran
Capra, Marcello
Cohen, Alan
Drelichman, Guillermo
Economou, Marina
Fattoum, Slaheddine
Kattamis, Antonis
Kilinc, Yurdanur
Perrotta, Silverio
Piga, Antonio
Porter, John B.
Griffel, Louis
Dong, Victor
Clark, Joan
Aydinok, Yesim
BLOOD, 2011, 118 (04) : 884 - 893
[4] SAFETY AND EFFICACY OF COMBINATION OF DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
Kakkar, S.
Sobti, P. C.
Jhinger, P. K.
HAEMATOLOGICA, 2014, 99 : 735 - 735
[5] EFFICACY AND SAFETY OF DEFERASIROX (EXJADE®) IN PEDIATRIC PATIENTS WITH B-THALASSEMIA MAJOR: 4.7-YEAR EXTENSION STUDY DATA
Piga, Antonio
Forni, Gian Luca
Kattamis, Antonis
Kattamis, Christos
Aydinok, Yesim
Rodriguez, Martha
Paley, Carole
Galanello, Renzo
PEDIATRIC BLOOD & CANCER, 2009, 52 (06) : 704 - 704
[6] Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia
Karimi, Mehran
Arandi, Nargess
Haghpanah, Sezaneh
Ansari, Shahla
Azarkeyvan, Azita
Bordbar, Mohammadreza
Safaei, Sanaz
HEMOGLOBIN, 2015, 39 (05) : 327 - 329
[7] Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial
Pennell, Dudley
Porter, John B.
Cappellini, Maria Domenica
Li, Chi-Kong
Aydinok, Yesim
Lee, Chan Lee
Kattamis, Antonis
Smith, Gillian
Habr, Dany
Domokos, Gabor
Hmissi, Abdel
Taher, Ali
BLOOD, 2008, 112 (11) : 1318 - 1318
[8] Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade®) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major
Cappellin, Maria Domenica
Elalfy, Mohsen Saleh
Kattamis, Antonis
Seymour, John F.
Lee, Chan Lee
Porter, John B.
El-Beshlawy, Amal
Habr, Dany
Domokos, Gabor
Hmissi, Abdel
Taber, Ali
BLOOD, 2008, 112 (11) : 1321 - 1321
[9] Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
Vichinsky, Elliott
Bernaudin, Francoise
Forni, Gian Luca
Gardner, Renee
Hassell, Kathryn
Heeney, Matthew M.
Inusa, Baba
Kutlar, Abdullah
Lane, Peter
Mathias, Liesl
Porter, John
Tebbi, Cameron
Wilson, Felicia
Griffel, Louis
Deng, Wei
Giannone, Vanessa
Coates, Thomas
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (03) : 387 - 397
[10] Deferasirox (Exjade®) in Pediatric Patients with β-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies
Piga, Antonio
Forni, Gian Luca
Kattamis, Antonis
Kattamis, Christos
Aydinok, Yesim
Rodriguez, Martha
Rojkjaer, Lisa
Galanello, Renzo
BLOOD, 2008, 112 (11) : 1323 - 1323

← 1 2 3 4 5 →